The Department of Science and Technology (DOST) said the “latest protocol" for the country’s eight month-long clinical trials seeking to assess the efficacy, safety, and effect on viral clearance of anti-parasitic drug Ivermectin in asymptomatic and mild coronavirus disease (COVID-19) patients...
The Department of Science and Technology (DOST) said Saturday, Oct. 23, said the recruitment of over 1,400 participants for the eight month-long clinical Ivermectin clinical trials is expected to start in November, and that the initial results of the study may be out by end of December this year....
Bracing for “good results,” the Department of Science and Technology (DOST) said Thursday, Oct. 21, that the drug developers and the public are expected to benefit from the country’s clinical trials seeking to assess the efficacy, safety, and effect on viral clearance of anti-parasitic drug...